Building Clinical Evidence Around Your Target Market: Interview with Teal Health CEO Kara Egan

About this episode

Kara Egan discusses building clinical evidence and market adoption strategies for Teal Health's cervical cancer screening technology.

In this episode of Medsider Radio, we sat down with Kara Egan , founder and CEO of Teal Health . Teal Health is the company behind the first FDA-authorized at-home cervical cancer screening wand. Before founding Teal, Kara worked in healthcare and software investing at .406 Ventures and Emergence Capital, and held product and marketing roles at Zendesk and Stitch Labs. In this interview, Kara discusses building support and follow-up into at-home screening, how Teal expanded its comparative clinical study to support broader market adoption, and how healthcare incentives, reimbursement, and institutional trust shape new care models. Before we dive into the discussion, I wanted to mention a few things: First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter. And if you’re ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization. These courses, featuring hard-earned lessons from elite…

People in this episode

Host: Scott Nelson

Guest: Kara Egan

Topics covered

• clinical evidence
• healthcare innovation
• cancer screening
• market adoption
• healthcare incentives

Keywords

• cervical cancer
• at-home screening
• clinical study
• healthcare incentives
• reimbursement

Mentioned in this episode

Organizations: Teal Health, .406 Ventures, Emergence Capital, Zendesk, Stitch Labs

More episodes of Medsider: Learn from Medtech and Healthtech Founders and CEOs

• Solving for Healthcare’s Broken Doorway: Interview with OnMed CEO Karthik Ganesh · June 1, 2026 · 51 min
• Meeting Patients Where They Are: Interview with Clairity CEO Dr. Connie Lehman · May 26, 2026 · 50 min
• Translating Academic IP into a Medtech Startup: Interview with Echopoint Medical CEO Antony Odell · May 18, 2026 · 52 min
• Why Early Revenue is the Most Credible Proof in Medtech: Interview with restor3d CEO Kurt Jacobus · May 12, 2026 · 55 min
• Finding the Clinical Need Hiding in Plain Sight: Interview with LightForce CEO Alfred Griffin · May 4, 2026 · 51 min
• Regulatory Rigor as a Competitive Moat: Interview with Osteoboost CEO Laura Yecies · April 6, 2026 · 54 min